These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388 [TBL] [Abstract][Full Text] [Related]
26. Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib. Ha YN; Song S; Orlikova-Boyer B; Cerella C; Christov C; Kijjoa A; Diederich M Mar Drugs; 2020 Jan; 18(1):. PubMed ID: 31963113 [TBL] [Abstract][Full Text] [Related]
27. A novel approach for relapsed/refractory FLT3 Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156 [TBL] [Abstract][Full Text] [Related]
28. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087 [No Abstract] [Full Text] [Related]
29. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. Allert C; Waclawiczek A; Zimmermann SMN; Göllner S; Heid D; Janssen M; Renders S; Rohde C; Bauer M; Bruckmann M; Zinz R; Pauli C; Besenbeck B; Wickenhauser C; Trumpp A; Krijgsveld J; Müller-Tidow C; Blank MF Leukemia; 2022 Oct; 36(10):2418-2429. PubMed ID: 36056084 [TBL] [Abstract][Full Text] [Related]
30. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Chang YT; Hernandez D; Alonso S; Gao M; Su M; Ghiaur G; Levis MJ; Jones RJ Blood Adv; 2019 Mar; 3(6):908-916. PubMed ID: 30898762 [TBL] [Abstract][Full Text] [Related]
31. Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy. Zhou S; Yang B; Xu Y; Gu A; Peng J; Fu J J Mol Model; 2022 Aug; 28(9):247. PubMed ID: 35932378 [TBL] [Abstract][Full Text] [Related]
32. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Marconi G; Giannini MB; Bagnato G; Simonetti G; Cerchione C; Mosquera Orgueira A; Musuraca G; Martinelli G Expert Opin Drug Saf; 2021 Jul; 20(7):791-799. PubMed ID: 33853481 [TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacological and clinical profile of gilteritinib (Xospata Mori M; Hidaka K Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479 [TBL] [Abstract][Full Text] [Related]
35. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Weis TM; Marini BL; Bixby DL; Perissinotti AJ Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288 [TBL] [Abstract][Full Text] [Related]
36. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560 [TBL] [Abstract][Full Text] [Related]
37. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia]. Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574 [TBL] [Abstract][Full Text] [Related]